**Supplementary Table 3**

Situations with potential to increase false-positive or false-negative rates of thrombophilia tests

|  |  |
| --- | --- |
| Situation | Tests Potentially Affected |
| Receiving anticoagulant therapy at time of test |  |
| Unfractionated heparin, low molecular weight heparin, rivaroxaban | Antithrombin AntigenAntithrombin, Enzymatic ActivityActivated Protein C (APC) ResistanceLupus AnticoagulantProtein C, FunctionalProtein C, TotalProtein S, FreeProtein S, FunctionalProtein S, Total |
| Warfarin | Activated Protein C (APC) ResistanceLupus AnticoagulantProtein C, FunctionalProtein C, TotalProtein S, FreeProtein S, FunctionalProtein S, Total |
| Acute thrombosis at time of test | Antithrombin AntigenAntithrombin, Enzymatic Activityβ2-glycoprotein 1, IgG Antibodiesβ2-glycoprotein 1, IgM AntibodiesCardiolipin IgG AntibodiesCardiolipin IgM AntibodiesLupus AnticoagulantProtein C, FunctionalProtein C, TotalProtein S, FreeProtein S, FunctionalProtein S, Total |
| Pregnant or < 8 weeks post-partum at time of test | Antithrombin AntigenAntithrombin, Enzymatic ActivityProtein C, FunctionalProtein C, TotalProtein S, FreeProtein S, FunctionalProtein S, Total |
| Receiving estrogen-containing medications at time of test | Protein S, FunctionalProtein S, Total |